New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever during the retreat from Russia.

A cluster contribution to European life science innovation and competitiveness?

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain.

Ny behandling för dödlig lungsjukdom – första på ett decennium

För första gången på över tio år har nu ett nytt läkemedel godkänts mot den svårbehandlade lungsjukdomen idiopatisk lungfibros, IPF.

Sarah Lidé: ”Artificial intelligence must not replace authentic interactions”

Artificial intelligence must never become a replacement for authentic, even if messy, interactions with our fellow humankind, Sarah Lifé, Deputy CEO at Medicon Village Innovation, writes in a column.

Heart Monitoring in Breast Cancer – Essential or Excessive?

Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.

Novo Nordisk planerar att kapa kostnader när konkurrensen hårdnar

Novo Nordisk slopar två fetmaläkemedel som en del av en omfattande översyn av forskningsportföljen. Samtidigt meddelar att avgående vd:n Lars Fruergaard Jørgensen att flera kostnadsbesparingar är att vänta.

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company will develop treatments for autoimmune diseases where there is currently a lack of effective therapies.

Kraftig viktnedgång i nya Novo Nordisk-studier

Två aktuella läkemedelsstudier från Novo Nordisk visar betydande viktminskning hos personer med fetma utan diabetes. Wegovy och det nya läkemedlet amycretin visar båda på över 20 procents viktminskning i kliniska studier.

Novo Nordisk går vidare med uppföljare till Ozempic

Novo Nordisk har beslutat att ta nästa generations viktminsknings- och diabetesläkemedel, amycretin, vidare till sen klinisk fas. En fas III-studie ska inledas i början på nästa år.

The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”

It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. "We invested for 25 years while everyone else laughed at us. Now everyone wants to join the game," says Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk.

Här är människorna bakom de utpekade rovförlagen

I en artikelserie har Life Science Sweden rapporterat om rovtidskrifter och om tidskriftskapare. Men vilka är människorna bakom? Spåren leder till framgångsrika entreprenörer, AI-genererade svar och ett publiceringsimperium som stämts för vilseledande affärsmetoder.

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in other wealthy countries — something he claims could reduce prices by 30 to 80 percent.

Oärliga företag tar över vetenskapliga tidskrifter – ”Ett allvarligt hot”

Oseriösa företag som köper upp vetenskapliga tidskrifter och sedan höjer publiceringsavgifterna och börjar masspublicera artiklar är ett växande problem. Läs första delen i Life Science Swedens artikelserie om rovtidskrifter.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away from us. They followed up by showering us with lawsuits,” he says.

Tidig tilläggsbehandling kan rädda liv på hjärtpatienter enligt studie

Tidig behandling med blodfettsänkande läkemedel ger en bättre prognos för patienter med hjärtinfarkt jämfört med en sent insatt behandling eller ingen behandling alls, enligt en registerstudie vid Lunds universitet.

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals on his podcasts.

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. Life Science Sweden reached out to him.

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclinical research about kidney diseases. “They are probably one of the most complicated organs in the body, and I like a challenge”, she says.

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO Sarah Fredriksson and is directed at biotech companies aiming to find a good licensing partner.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious career – as an increasingly important model organism in medical research.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies: to succeed with a licensing deal.

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.